Lynparza delays disease progression in phase III trial for ovarian cancer

04:05 EDT 28 Jun 2018 | Pharmaceutical Business Review

AstraZeneca and Merck have announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets.

More From BioPortfolio on "Lynparza delays disease progression in phase III trial for ovarian cancer"